Key result
TUDCA prevents cardiac fibrosis and improves exercise tolerance in preclinical heart failure.
Why the study?
Cardiac fibrosis is difficult to treat clinically due to lack of understanding of molecular mechanisms and effective anti-fibrotic therapies.
Does tauroursodeoxycholic acid (TUDCA) prevent cardiac fibrosis in a mouse model of heart failure?
Does tauroursodeoxycholic acid (TUDCA) prevent cardiac fibrosis in a mouse model of heart failure?
Pharmacological inhibition of the unfolded protein response pathway by TUDCA prevents cardiac fibrosis and improves exercise tolerance in a mouse model of heart failure.
Answers are grounded in this paper and cite their sources.
TUDCA attenuates fibrosis in murine HF; hypothesis-generating and should not change clinical practice.
BACKGROUND: Cardiac fibrosis attributed to excessive deposition of extracellular matrix proteins is a major cause of heart failure and death. Cardiac fibrosis is extremely difficult and challenging to treat in a clinical setting due to lack of understanding of molecular mechanisms leading to cardiac fibrosis and effective anti-fibrotic therapies. The objective in this study was to examine whether unfolded protein response (UPR) pathway mediates cardiac fibrosis and whether a pharmacological intervention to modulate UPR can prevent cardiac fibrosis and preserve heart function. METHODOLOGY/PRINCIPAL FINDINGS: We demonstrate here that the mechanism leading to development of fibrosis in a mouse with increased expression of calreticulin, a model of heart failure, stems from impairment of endoplasmic reticulum (ER) homeostasis, transient activation of the unfolded protein response (UPR) pathway and stimulation of the TGFβ1/Smad2/3 signaling pathway. Remarkably, sustained pharmacologic inhibition of the UPR pathway by tauroursodeoxycholic acid (TUDCA) is sufficient to prevent cardiac fibrosis, and improved exercise tolerance. CONCLUSIONS: We show that the mechanism leading to development of fibrosis in a mouse model of heart failure stems from transient activation of UPR pathway leading to persistent remodelling of cardiac tissue. Blocking the activation of the transiently activated UPR pathway by TUDCA prevented cardiac fibrosis, and improved prognosis. These findings offer a window for additional interventions that can preserve heart function.
No takes yet. Share an insight, caveat, or question.
Groenendyk et al. (2016) studied Cardiac fibrosis and heart failure (n=162). Tauroursodeoxycholic acid (TUDCA) vs. Control diet/water was evaluated on Cardiac fibrosis (collagen deposition area) (p=<0.01). Sustained pharmacologic inhibition of the unfolded protein response pathway by tauroursodeoxycholic acid (TUDCA) prevented cardiac fibrosis and improved exercise tolerance in a mouse model of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: